
Exciting early data for ENPP3×CD3 bispecifics in heavily pretreated #RCC ~45% ORR suggests quite some real potential. Definitely a space to watch l #ESMO26 #KidneyCancer @montypal @Uromigos @oncodaily @OncoDailyGU
✓Professor of Urology, Urologic Oncology, Sports Medicine @LMU_Muenchen; Vice President, Global Head of Clinical Development; 🚵♀️Passionate Cyclist

Exciting early data for ENPP3×CD3 bispecifics in heavily pretreated #RCC ~45% ORR suggests quite some real potential. Definitely a space to watch l #ESMO26 #KidneyCancer @montypal @Uromigos @oncodaily @OncoDailyGU

Radiopharmaceuticals in #ProstateCancer Part 4A: Endpoints, Immunotherapy, and Future Directions - Michael Morris, MD & @DrRanaMcKay join @DrPhilKantoff to discuss regulatory endpoints and emerging immunotherapy strategies in advanced prostate cancer. They review progress toward incorporating PSMA PET into regulatory frameworks under Prostate Cancer Working Group 4 and highlight several T-cell engagers under development, including xaluritamig advancing to phase 3, pasritamig with PSA-90 responses in 75% of patients combined with docetaxel, and VIR-5818, a PSMA-directed bispecific using protease-cleavable masking to limit systemic toxicity. #WatchNow > bit.ly/4ueYaxk @PCFnews @ConvergentRx

🎯 Mature THOR data confirm that FGFR3 is an actionable target in metastatic urothelial cancer! Erdafitinib vs chemotherapy: 🔹 OS: 12.1 vs 8.7 months (HR 0.65) 🔹 ORR: 46.9% vs 12.6% But the survival curves also highlight the challenge: most patients progress. How can we achieve more durable responses? Overcoming adaptive resistance will be key. NRG1–ERBB signaling is one intriguing avenue, as explored in our previous work (Hosni et al. @CR_AACR) Could rational combinations, including FGFR inhibition + EV, improve outcomes? FORAGER-2 is particularly interesting @EliLillyandCo @loredana_puca Precision targeting works. Now we need to make responses last. 🔬 @OncoAlert @weoncologists @urotoday @Uromigos @OncoAlert and Faculty: @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @Markuseckstein3

🚀 Is GU oncology becoming one of the most exciting fields for molecular imaging & theranostics? PSMA in prostate cancer, CAIX in clear-cell RCC, and emerging NECTIN4-targeted approaches in urothelial cancer! Fantastic to see CAIX imaging on the cover of The Lancet Medical Imaging & Theranostics. CAIX is a particularly elegant target: VHL loss → HIF stabilization → CAIX upregulation in ccRCC. Using tumor biology wisely! 🧬 The opportunity goes beyond detecting disease: molecular imaging could enable patient selection, visualize target heterogeneity and potentially guide radioligand therapy. Of course, CAIX-directed theranostics still require prospective validation, particularly of therapeutic efficacy and safety. Exciting times for precision GU oncology! 👏 Read here: sciencedirect.com/science/ar… @ProfKHerrmann #KidneyCancer #Theranostics #GUOncology @weoncologists @urotoday @Uromigos @OncoAlert and Faculty: @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @Markuseckstein3

🚀 Exciting work by @brian_rini and colleagues! IRIS-RCC brings us closer to reproducible, individual-sample molecular subtyping in RCC. We are exploring a complementary approach in mRCC: vascular architecture as a biomarker of IO sensitivity, assessed on routine H&E or CD31 IHC. Our initial data suggest that low vessel branching may enrich for IO response, while our vascular score has also shown baseline prognostic value in CheckMate 914. The exciting opportunity: a potentially scalable, pathology-based biomarker that could be easier to integrate into routine clinical workflows. Next step: validation in digitized H&E from large, randomized mRCC cohorts—critically, to distinguish predictive from prognostic value. Our preprint 👇 medrxiv.org/content/10.1101/… @OncoAlert @weoncologists @DrChoueiri

Free education and networking event for GU oncology in La Jolla next week. @OncLive @DrRanaMcKay Rahul Aggarwal @YuWeiChenMD @UCSFCancer @UCSDCancer Would love to see you + your colleagues: @montypal @AmarUKishan @Adam_Weiner535 @jgong15 @yunroseli @EdwinPosadasMD

Interesting data from Phase 2 study #COMRADE at #ESMO26: Early on-treatment #ctDNA may help identify patients at risk of progression after just one cycle of #radium223. Possibly one more step toward biomarker-guided, adaptive radiopharmaceutical therapy. We are getting more and more evidence about a potential key prognostic role of ctDNA also in #ProstateCancer including evidence that it may be used as a guide for treatment modulation - it will be most important now to prospectively include ctDNA in more trials and further validate it #mCRPC #RLT #Olaparib #radium223 @urotoday @oncodaily @OncoDailyGU @DrRanaMcKay

And confirmed again that #PSA Nadir (cut-off 0.2 l) is a strong prognostic factor and predictor of oncological outcomes OS, CRPC-FS in patients with #mAPMS PC. A higher proportion of patients treated with ADT+ARPI compared to ADT+Docetaxel or ADT+D+ARPI achieved a deep PSA response - would be very interested in seeing the breakdown per treatment in both low and high volume categories, but I guess the nadir achieved reflects predominantly more aggressive disease rather than a treatment effect #ProstateCancer #UrologicOncology #PSANadir #Biomarkers @oncodaily @OncoDailyGU @urotoday @chavarriagaj

Just happened today👏🎉👉 @FDA approved Talazoparib + enzalutamide for pts with HRRm positive mAPMS/mHSPC #prostatecancer FDA Link👉 l1nq.com/ltlq6jk 👉 @NEJM paper tinyurl.com/vkvra8cd 👇 @ASCO @oncoalert @urotoday @PCF_Science @DanaFarber_GU

LuCAB at #ESMO26 - Combination Lu-177 PSMA-617 + cabazitaxel in mCRPC, accepted in @TheLancetOncol Adding taxane chemotherapy to LuPSMA may overcome heterogeneous PSMA expression and act as a radiosensitiser. 35 pts, post-docetaxel + ARPI: 🧪 No DLTs: cabazitaxel 20 mg/m2 + 7.4 GBq LuPSMA ⚠️ G3 TRAEs 24%, no G4/5 📈 RP2D (n=26): PSA50 73%, rPFS 10.9 mo, OS 16.5 mo Impressive outcomes in an unfavourable cohort (29% M1c). Randomised trials needed: chemo + LuPSMA together or in sequence? 🙏 Led by @LouiseKostos & @AzadOncology with @ButeauJames , Grace Kong, @pj_physics, @DrBenTran, @MHaskali, @declangmurphy @PeterMacCC and @drlouiseemmett @StVincentsSyd Above all, thank you to the patients and families who took part. Funded by @PCFnews through @pros_tic , with PSMA-617 supplied by @Novartis plus additional support. @myESMO

While DASL-HiCaP reinforces ARPI intensification, important questions remain @Silke_Gillessen Why positive #STAMPEDE/#DASL-HiCaP, yet not #ENZARAD? Which high-risk patients benefit most? Primary vs salvage RT? And how does #PROTEUS reshape intensification around surgery? #Enzalutamide #Apalutamide #Darolutamide ❓Different risk definitions and primary vs salvage settings complicate comparisons. ❓Who truly needs ARPI intensification, and when? What is the additive role of #RadiationTherapy and #RadicalProstatectomy ❓With PROTEUS extending the discussion to prostatectomy, better patient selection and identifying the best prognostic and predictive biomarkers reflecting specific early/local/locally advanced indications remains key #ESMO26 #ProstateCancer #UrologicOncology @oncodaily @OncoDailyGU @urotoday

Positive DASL-HiCaP results presented at #ESMO26 @niazi_Dr7 👍Adding #darolutamide to ADT + RT in very-high-risk #ProstateCancer improved ✅4-year MFS (95% vs 88%; HR 0.42), ✅delayed CRPC (HR 0.22) ✅increased time to subsequent hormonal therapy (HR 0.36) All clinically meaningful benefits, while OS remains immature. #ProstateCancer #Radiationtherapy #UrologicOncology @oncodaily @OncoDailyGU @urotoday @ChrisSweens1

Dear GU colleagues at #ESMO26! Dr. Silke Gillessen 🇨🇭invites you to the inaugural LPCCC – Localised Prostate Cancer Consensus Conference! 🔬 CALL FOR ABSTRACTS NOW OPEN! 👉 Submit your abstract: apccc.org/call-for-abstracts 📅 LPCCC 2027 | 29 April – 1 May 2027 We invite our colleagues in #ProstateCancer to submit their abstracts and contribute to shaping the discussion on the diagnosis and clinical management of men with localised prostate cancer. LPCCC marks an exciting evolution of the APCCC family, extending the consensus-conference concept to localised disease, with a particular focus on areas where evidence, guidelines and clinical practice leave important questions unanswered. Two days of high-level presentations, discussion and debate will bring together the latest evidence and expert perspectives to address the questions that matter most in everyday clinical practice. We look forward to your contributions! #LPCCC27 #ProstateCancer #ASTRO26 @APCCC_Lugano, @BertrandTOMBAL, @ChrisSweens1, @jmmrad, @drjefstathiou, @CaPsurvivorship, @LoebStacy, @charlesryanmd, @AarmstrongDuke, @Ecastromarcos, @LVM_Walz, @piet_ost, @Nicola_Fossati, @AnthonyMJoshua, @Prof_Nick_James, @VedangMurthy, @AttardLab, @Silke_Gillessen, @AOmlin, @ProfKHerrmann Pinging @AmandaNizamMD, @scocmem, @nataliagandur, @gu_onc, @tompowles1, @brian_rini, @declangmurphy, @cdanicas, @neerajaiims

Honoured to have had the opportunity to present "Optimal induction treatment in non-metastatic bladder cancer" at #ESMO26 in Madrid! 🚨 Does a deeper pathological response translate into greater survival benefit in perioperative MIBC? An intriguing pattern across four phase III trials: 🔹 NIAGARA: ΔpCR +10 pp | EFS HR 0.68 🔹 KEYNOTE-B15: +23 pp | HR 0.53 🔹 VOLGA: +32 pp | HR 0.51 🔹 KEYNOTE-905: +49 pp | HR 0.40 Larger absolute pCR gains appear to track with greater EFS benefit. But the comparator matters! KEYNOTE-905 and VOLGA used surgery-based controls without neoadjuvant systemic therapy (control "pCR" ~8–9%), whereas NIAGARA and KEYNOTE-B15 used active neoadjuvant cisplatin-based chemotherapy. Thus, the magnitude of ΔpCR is not directly comparable across trials. The key question: Can pCR, combined with utDNA + ctDNA clearance, become a reliable tool for response-adapted treatment intensity? ⚠️ This is an exploratory, trial-level observation—not proof that pCR improvements cause EFS benefits or that pCR is a validated surrogate endpoint! Better biomarkers could help us maximize cure while minimizing overtreatment. 🔬 #ESMO26 #BladderCancer @weoncologists @urotoday @Uromigos @OncoAlert Faculty: @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @Markuseckstein3


🚨📣📣 #ESMO26 presidential: @niazi_Dr7 Adding darolutamide to ADT + RT dramatically ⬇️ risk of metastasis or death in high-risk localized prostate cancer. Phase 3 DASL-HiCaP = 58% ⬇️ in MFS (HR 0.42) + early OS signal (HR 0.88). #ProstateCancer #RadOnc #pcsm @ChrisSweens1